Literature DB >> 31414902

CT Characteristics of Non-Small Cell Lung Cancer With Anaplastic Lymphoma Kinase Rearrangement: A Systematic Review and Meta-Analysis.

Tae-Hyung Kim1,2, Sungmin Woo3, Soon Ho Yoon1,3, Darragh F Halpenny3, Sangwon Han4, Chong Hyun Suh5.   

Abstract

OBJECTIVE. The purpose of this study was to perform a systematic review and meta-analysis regarding CT features of non-small cell lung cancer (NSCLC) with anaplastic lymphoma kinase (ALK) rearrangement. MATERIALS AND METHODS. The PubMed and Embase databases were searched up to February 20, 2019. Studies that evaluated CT features of NSCLC with and without ALK rearrangement was included. Methodologic quality was assessed using Quality Assessment of Diagnostic Accuracy Studies-2. The association between CT features and ALK rearrangement was pooled in the form of the odds ratio (OR) or the mean difference (MD) using the random-effects model. Heterogeneity was examined using the inconsistency index (I2). Publication bias was examined using funnel plots and Egger tests. RESULTS. Sixteen studies were included, consisting of 3113 patients with NSCLC. The overall prevalence of patients with ALK rearrangement was 17% (528/3113). Compared with NSCLC without ALK rearrangement, on CT images those with ALK rearrangement were more frequently solid (OR = 2.86), central in location (OR = 2.72), and 3 cm or smaller (OR = 0.57); had lower contrast-enhanced CT attenuation (MD = -4.79 HU); more frequently had N2 or N3 disease (OR = 5.63), lymphangitic carcinomatosis (OR = 3.46), pleural effusion (OR = 1.91), or pleural metastasis (OR = 1.81); and less frequently had lung metastasis (OR = 0.66). Heterogeneity varied among CT features (I2 = 0-80%). No significant publication bias was seen (p = 0.15). CONCLUSION. NSCLC with ALK rearrangement had several distinctive CT features compared with that without ALK rearrangement. These CT biomarkers may help identify patients likely to have ALK rearrangement.

Entities:  

Keywords:  CT; anaplastic lymphoma kinase; meta-analysis; non–small cell lung cancer; systematic review

Mesh:

Substances:

Year:  2019        PMID: 31414902      PMCID: PMC7513933          DOI: 10.2214/AJR.19.21485

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  41 in total

1.  Quantifying heterogeneity in a meta-analysis.

Authors:  Julian P T Higgins; Simon G Thompson
Journal:  Stat Med       Date:  2002-06-15       Impact factor: 2.373

2.  Clinical and CT characteristics of surgically resected lung adenocarcinomas harboring ALK rearrangements or EGFR mutations.

Authors:  Robert J Gillies; Zhaoxiang Ye; Hua Wang; Matthew B Schabath; Ying Liu; Ying Han; Qi Li
Journal:  Eur J Radiol       Date:  2016-08-30       Impact factor: 3.528

3.  Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.

Authors:  Solange Peters; D Ross Camidge; Alice T Shaw; Shirish Gadgeel; Jin S Ahn; Dong-Wan Kim; Sai-Hong I Ou; Maurice Pérol; Rafal Dziadziuszko; Rafael Rosell; Ali Zeaiter; Emmanuel Mitry; Sophie Golding; Bogdana Balas; Johannes Noe; Peter N Morcos; Tony Mok
Journal:  N Engl J Med       Date:  2017-06-06       Impact factor: 91.245

4.  Clinicoradiologic characteristics of patients with lung adenocarcinoma harboring EML4-ALK fusion oncogene.

Authors:  Takayuki Fukui; Yasushi Yatabe; Yoshihisa Kobayashi; Kenji Tomizawa; Simon Ito; Shunzo Hatooka; Keitaro Matsuo; Tetsuya Mitsudomi
Journal:  Lung Cancer       Date:  2012-04-06       Impact factor: 5.705

5.  Comparative analysis of clinicoradiologic characteristics of lung adenocarcinomas with ALK rearrangements or EGFR mutations.

Authors:  J Y Zhou; J Zheng; Z F Yu; W B Xiao; J Zhao; K Sun; B Wang; X Chen; L N Jiang; W Ding; J Y Zhou
Journal:  Eur Radiol       Date:  2015-01-11       Impact factor: 5.315

6.  NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 5.2018.

Authors:  David S Ettinger; Dara L Aisner; Douglas E Wood; Wallace Akerley; Jessica Bauman; Joe Y Chang; Lucian R Chirieac; Thomas A D'Amico; Thomas J Dilling; Michael Dobelbower; Ramaswamy Govindan; Matthew A Gubens; Mark Hennon; Leora Horn; Rudy P Lackner; Michael Lanuti; Ticiana A Leal; Rogerio Lilenbaum; Jules Lin; Billy W Loo; Renato Martins; Gregory A Otterson; Sandip P Patel; Karen Reckamp; Gregory J Riely; Steven E Schild; Theresa A Shapiro; James Stevenson; Scott J Swanson; Kurt Tauer; Stephen C Yang; Kristina Gregory; Miranda Hughes
Journal:  J Natl Compr Canc Netw       Date:  2018-07       Impact factor: 11.908

7.  Metabolic and metastatic characteristics of ALK-rearranged lung adenocarcinoma on FDG PET/CT.

Authors:  Hongyoon Choi; Jin Chul Paeng; Dong-Wan Kim; June Koo Lee; Chang Min Park; Keon Wook Kang; June-Key Chung; Dong Soo Lee
Journal:  Lung Cancer       Date:  2012-12-20       Impact factor: 5.705

8.  Clinical characteristics of patients with non-small cell lung cancers harboring anaplastic lymphoma kinase rearrangements and primary lung adenocarcinoma harboring epidermal growth factor receptor mutations.

Authors:  L Xu; J Lei; Q Z Wang; J Li; L Wu
Journal:  Genet Mol Res       Date:  2015-10-21

9.  Tracking the Evolution of Non-Small-Cell Lung Cancer.

Authors:  Mariam Jamal-Hanjani; Gareth A Wilson; Nicholas McGranahan; Nicolai J Birkbak; Thomas B K Watkins; Selvaraju Veeriah; Seema Shafi; Diana H Johnson; Richard Mitter; Rachel Rosenthal; Max Salm; Stuart Horswell; Mickael Escudero; Nik Matthews; Andrew Rowan; Tim Chambers; David A Moore; Samra Turajlic; Hang Xu; Siow-Ming Lee; Martin D Forster; Tanya Ahmad; Crispin T Hiley; Christopher Abbosh; Mary Falzon; Elaine Borg; Teresa Marafioti; David Lawrence; Martin Hayward; Shyam Kolvekar; Nikolaos Panagiotopoulos; Sam M Janes; Ricky Thakrar; Asia Ahmed; Fiona Blackhall; Yvonne Summers; Rajesh Shah; Leena Joseph; Anne M Quinn; Phil A Crosbie; Babu Naidu; Gary Middleton; Gerald Langman; Simon Trotter; Marianne Nicolson; Hardy Remmen; Keith Kerr; Mahendran Chetty; Lesley Gomersall; Dean A Fennell; Apostolos Nakas; Sridhar Rathinam; Girija Anand; Sajid Khan; Peter Russell; Veni Ezhil; Babikir Ismail; Melanie Irvin-Sellers; Vineet Prakash; Jason F Lester; Malgorzata Kornaszewska; Richard Attanoos; Haydn Adams; Helen Davies; Stefan Dentro; Philippe Taniere; Brendan O'Sullivan; Helen L Lowe; John A Hartley; Natasha Iles; Harriet Bell; Yenting Ngai; Jacqui A Shaw; Javier Herrero; Zoltan Szallasi; Roland F Schwarz; Aengus Stewart; Sergio A Quezada; John Le Quesne; Peter Van Loo; Caroline Dive; Allan Hackshaw; Charles Swanton
Journal:  N Engl J Med       Date:  2017-04-26       Impact factor: 91.245

Review 10.  CT characteristics of non-small cell lung cancer with epidermal growth factor receptor mutation: a systematic review and meta-analysis.

Authors:  Zenghui Cheng; Fei Shan; Yuesong Yang; Yuxin Shi; Zhiyong Zhang
Journal:  BMC Med Imaging       Date:  2017-01-10       Impact factor: 1.930

View more
  3 in total

1.  Differentiating synchronous double primary lung adenocarcinomas from intrapulmonary metastasis by CT features, EGFR mutations and ALK rearrangement status.

Authors:  Xiaoyu Han; Jun Fan; Tong Liu; Na Li; Osamah Alwalid; Jin Gu; Heshui Shi
Journal:  J Thorac Dis       Date:  2020-10       Impact factor: 2.895

2.  Random Walk Algorithm-Based Computer Tomography (CT) Image Segmentation Analysis Effect of Spiriva Combined with Symbicort on Immunologic Function of Non-Small-Cell Lung Cancer.

Authors:  Xiaodan Li; Wei Liu; Mianjie Liang; Zengtao Sun
Journal:  Comput Math Methods Med       Date:  2022-06-03       Impact factor: 2.809

3.  [Relationship between EGFR, ALK Gene Mutation and Imaging 
and Pathological Features in Invasive Lung Adenocarcinoma].

Authors:  He Yang; Zicheng Liu; Hongya Wang; Liang Chen; Jun Wang; Wei Wen; Xinfeng Xu; Quan Zhu
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2022-03-20
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.